x
Breaking News
0

Incyte Corporation (INCY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Incyte's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
86.03 +0.44    +0.51%
16/02 - Closed. Currency in USD ( Disclaimer )
After Hours
86.60
+0.57
+0.66%
22:56:39 GMT - Real-time Data
Type: Equity
Market: United States
ISIN: US45337C1027 
CUSIP: 45337C102
  • Volume: 2,473,939
  • Bid/Ask: 85.66 / 88.80
  • Day's Range: 84.51 - 88.23
Incyte 86.03 +0.44 +0.51%

INCY Overview

 
Information about the Incyte Corporation Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close85.59
Day's Range84.51 - 88.23
Revenue1.54B
Open85.55
52 wk Range80.85 - 153.15
EPS - 1.56
Volume2,473,939
Market Cap18.16B
Dividend (Yield)0 (N/A)
Average Vol. (3m)1,677,151
P/E RatioN/A
Beta0.62
1-Year Change - 28.6%
Shares Outstanding211,663,861
Next Earnings DateMay 02, 2018
What is your sentiment on Incyte?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Strong Sell Strong Sell Strong Sell Sell
Technical Indicators Strong Sell Strong Sell Sell Strong Sell Strong Sell
Summary Strong Sell Strong Sell Strong Sell Strong Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Completed Patterns
Three Inside Up 1D 4 Feb 12, 2018
Falling Three Methods 1D 6 Feb 08, 2018
Doji Star Bearish 5H 6 Feb 13, 2018 03:00PM
Bullish Engulfing 1D 8 Feb 06, 2018
Engulfing Bearish 1M 10 Apr 17

Incyte Corporation News & Analysis

Incyte Corporation Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 86.03 85.66 88.80 2,473,939 +0.51% USD 16/02  
  Berlin 69.64 69.08 70.11 0 -1.50% EUR 07:18:00  
  Stuttgart 68.88 68.88 69.87 0 -2.31% EUR 07:43:00  
  Munich 69.01 69.08 70.10 0 +0.15% EUR 07:00:00  
  Vienna 71.000 0.000 0.000 0 0% EUR 15/02  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Punjab National Bank 115.65 123.50 113.55 -9.90 -7.89% 99.11M 08:13:55  
  SBI 260.85 272.00 256.65 -10.80 -3.98% 26.94M 08:14:25  
  Apple 172.43 174.82 171.77 -0.56 -0.32% 40.18M 16/02  
  Daimler 71.120 71.470 70.860 -1.380 -1.90% 0 08:14:45  
  Amazon.com 1,448.69 1,465.80 1,446.56 -13.07 -0.89% 4.47M 16/02  
  Tata Steel Ltd 643.65 693.40 639.00 -46.10 -6.68% 12.55M 08:14:25  
  Kotak Mahindra Bank 1,055.00 1,059.00 1,046.55 +4.80 +0.46% 818.00K 08:14:18  
  Alibaba 183.68 188.27 183.54 -3.77 -2.01% 16.11M 16/02  
  Deutsche Bank AG 13.115 13.120 13.045 +0.193 +1.49% 0 08:14:11  
  Tesla 335.49 343.12 331.64 +1.42 +0.43% 5.64M 16/02  

Incyte Corporation Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

980

Equity Type

ORD

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading
National Futures Association (United States), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Australian Securities and Investments Commission (Australia), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States) $10000 Start Trading

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Are you sure you want to delete this chart?
 
Write your thoughts about Incyte Corporation
 
Replace the attached chart with a new chart ?
Post
Post also to:
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

Latest INCY Comments

Giacomo Carducci
Giacomo Carducci Feb 13, 2018 11:37PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Also, one of the finest stock research letters (Oxford Communique) loved it at $100 and deemed it one of their Ten-Bagger portfolio stocks. The Oxford Club knows what they're talking about too.
Reply
0 0
Giacomo Carducci
Giacomo Carducci Feb 13, 2018 11:33PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock is conservatively worth $105. I wouldn't be surprised if its closer to $175 than $100 by the end of the yr.
Reply
0 0
Giacomo Carducci
Giacomo Carducci Feb 13, 2018 11:35PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Also, one of the finest stock research letters (Oxford Communique) loved it at $100 and deemed it one of their Ten-Bagger portfolio stocks. The Oxford Club knows what they're talking about too.
Reply
0 0
 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post 1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email